Harper Molly 4
4 · CATALYST PHARMACEUTICALS, INC. · Filed Nov 29, 2024
Insider Transaction Report
Form 4
Harper Molly
Director
Transactions
- Exercise/Conversion
Common stock, par value $0.001 per share
2024-11-27$5.78/sh+17,500$101,150→ 17,500 total - Sale
Common stock, par value $0.001 per share
2024-11-27$22.00/sh−17,500$385,000→ 0 total - Exercise/Conversion
Options to purchase common stock
2024-11-27−17,500→ 134,020 totalExercise: $5.78Exp: 2028-06-29→ Common Stock (17,500 underlying)
Footnotes (2)
- [F1]Shares were sold on the open market for personal reasons and to fund the exercise price of the stock options, and not as a result of any disagreement with the Company.
- [F2]Options vested in three annual tranches beginning on June 29, 2022.